Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism, PK and Absolute Bioavailability of Avenciguat in Healthy Males
NCT05515328Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avenciguat in Portal Hypertension (PH), Cirrhosis, diabetic kidney disease (DKD) and 1 more (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Fraction of [¹⁴C] radioactivity excreted into urine (fe urine,0-tz) up to 14 days, Fraction of [¹⁴C] radioactivity excreted into feces (fe feces,0-tz) up to 14 days and 1 more. Started Sep 2022; status: completed.
02
Drugs
avenciguat
03
Conditions
Portal Hypertension (PH)Cirrhosisdiabetic kidney disease (DKD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT05515328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515328.